Back to Parexel Insights

The future of Parkinson’s Disease treatment: From digital measures to disease modification

By Andreas Lysandropoulos, M.D., Ph.D., Senior Vice President, Global Therapeutic Area Head, Neuroscience
Nathan Noakes, Sensor Solutions Director
Jeffrey Abraham, Health Advances Partner

Dr. Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Head of Neurosciences, leads a panel with ActiGraph's Chief Scientific Officer Christine Guo, and Health Advance's Partner Jeff Abraham on “The future of Parkinson’s Disease treatment: From digital measures to disease modification.” Parexel's own Sensor Solutions Director, Nathan Noakes, also joins them to discuss the challenges in developing disease-modifying therapies, the role of digital health technologies, and the integration of digital endpoints in clinical trials. The panel explores how wearables and big data can revolutionize Parkinson’s care and the importance of real-world evidence in regulatory decisions.

Part 1: The state of Parkinson’s care: Challenges and opportunities

The panel explores the current landscape of Parkinson's disease, highlighting existing treatments and the integration of digital measures. They emphasize the challenges in developing disease-modifying therapies and the importance of precise, objective measures to track disease progression.

The panel explores the current landscape of Parkinson's disease, highlighting existing treatments and the integration of digital measures. They emphasize the challenges in developing disease-modifying therapies and the importance of precise, objective measures to track disease progression.

Part 2: Addressing key hurdles in Parkinson’s patient care

The panel discusses the challenges Parkinson's patients face, emphasizing the need for patient-centric digital solutions that reduce burden and improve data collection. They highlight the importance of usability research, continuous data collection, and the integration of digital tools in clinical trials to enhance patient outcomes and support disease-modifying therapies.

Part 3: Addressing key hurdles in Parkinson’s patient care

The panel discusses the importance of patient compliance and real-time data in digital health solutions for Parkinson's. They emphasize user-centered design, patient education, and data protection to ensure technology acceptance and adherence. The discussion also covers regional differences in regulatory and payer assessments of digital health technologies.

The panel discusses the importance of patient compliance and real-time data in digital health solutions for Parkinson's. They emphasize user-centered design, patient education, and data protection to ensure technology acceptance and adherence. The discussion also covers regional differences in regulatory and payer assessments of digital health technologies.

Part 4: Shaping tomorrow’s Parkinson’s therapies: Digital tools and disease modification

The panel discusses the future of Parkinson's disease treatment, focusing on the shift from symptomatic to disease-modifying therapies. They highlight the role of digital health in shaping new drug development programs, the importance of global regulatory perspectives, and the potential of big data to accelerate the development and approval of disease-modifying therapies that will change lives.

Contributing Experts

Andreas Lysandropoulos, M.D., Ph.D.

Senior Vice President, Global Therapeutic Area Head, Neuroscience

Read bio

Nathan Noakes

Sensor Solutions Director

Read bio

Jeffrey Abraham

Health Advances Partner

Read bio

Learn what's possible now

Stay current with novel thinking and actionable insights from our experts.

Start a conversation

Learn more about how Parexel is accelerating neuroscience

At Parexel, we advise sponsors on strategies to accelerate development timelines and effective ways to support approval and access to new neuroscience treatments. Sponsors can take calculated risks in this fast-evolving scientific and regulatory environment, such as utilizing novel biomarkers and endpoints, innovative trial designs, patient-guided feasibility testing, a bespoke regulatory strategy, and real-world evidence. We help them mitigate risks with expertise gained from experience.

In the past five years, our neuroscience-focused team of patient advocates, clinicians, scientists, statisticians, and former regulators has partnered with sponsors for more than 600 clinical and consulting projects, enrolling 47,000 patients.

Learn More